The FDA’s warning letter to WHOOP centers on its Blood Pressure Insights feature, which regulators say functions as an unapproved medical device. The agency argues that estimating blood pressure crosses from wellness tracking into clinical use, triggering federal rules that require testing, validation, and formal clearance. The move signals tougher oversight for wearables offering health-style metrics, raising new regulatory and financial hurdles for smaller device makers.
FULL STORY - THREE VIEWS
Industry-Wide Implications of the FDA’s Warning Letter
The wearable-tech boom has entered a new, more uncertain chapter. As consumer demand for advanced health metrics rises, regulatory pressure is mounting — and the recently issued warning letter to WHOOP may be a bellwether for what’s to come.
In July 2025, the U.S. Food and Drug Administration (FDA) formally flagged the “Blood Pressure Insights” (BPI) feature from WHOOP, asserting the feature qualifies as an unapproved medical device. WHOOP, which markets sleep trackers, recovery bracelets, and other gear designed for fitness and wellness, had previously operated under a “regulatory gray zone,” offering health-adjacent features without formal clearance.
WHOOP’s BPI claims to provide daily estimations of systolic and diastolic blood pressure. According to the FDA warning letter, the company marketed BPI as delivering “medical-grade health & performance insights,” and described how “blood pressure affects sleep, recovery, and performance.” Because the intended use includes estimating blood pressure — a core factor in diagnosing conditions like hypertension — the FDA determined the BPI function crosses into regulated medical-device territory. Under federal law, this means WHOOP’s marketing and distribution of BPI were both “adulterated” and “misbranded” without prior approval or 510(k) clearance.
WHOOP’s response: the company stands by BPI as a “wellness feature,” not a medical device. Its representatives argued that blood pressure tracking via sleep-based estimations and optical sensors is conceptually no different from tracking metrics like respiratory rate or heart-rate variability. They pointed to the 21st Century Cures Act, which carves out a “general wellness” exception for certain health-adjacent software. WHOOP’s CEO has reportedly called the FDA’s enforcement “regulatory overreach,” vowing not to remove BPI despite the agency’s demand to comply.
Whether the FDA siding more strictly with blood-pressure features makes sense depends on perspective. On one hand, blood pressure is widely recognized as a key modifiable risk factor for cardiovascular disease. In the clinic, accuracy matters — a late or misleading reading could lull someone into unwarranted confidence, or cause unnecessary alarm. The FDA noted that even occasional misreads pose significant risk, especially if users rely on them to avoid medical care. It also emphasized that the agency already regulates traditional cuff-based and other noninvasive blood-pressure monitors, so wrist-worn estimators aren’t exempt simply because they rely on different technology.
On the other hand, critics argue that labeling wellness wearables as medical devices whenever they touch on “clinical” metrics could stifle innovation. Startups and niche products may not have the resources for extensive clinical trials and compliance efforts. This could particularly disadvantage smaller players vying to differentiate themselves against giants like Apple or Samsung, which have deeper pockets and existing compliance infrastructure.
The economic stakes are high. The global wearables market is estimated in the tens of billions of dollars, and rapid growth has been driven by consumer appetite for more detailed biometric data. Increased regulatory costs could slow product launches, reduce feature sets, or discourage companies from entering the space altogether.
Some companies are already adapting. Other wrist-band makers have sought or obtained clearance from the FDA or have avoided features explicitly tied to blood pressure for the U.S. market. The contrast between compliance-seeking firms and those resisting the FDA’s interpretation highlights a potential bifurcation in the wearables industry: devices built as medical tools versus streamlined wellness trackers designed to avoid regulatory entanglement.
Meanwhile, the broader regulatory environment is evolving. The FDA appears less tolerant of claims that borderline on medical use, particularly in categories that carry significant health consequences — like blood pressure. Legal experts warn that the BPI warning letter may signal the agency is shifting away from the enforcement discretion enshrined in its 2019 “General Wellness Policy.”
Ultimately, the WHOOP case may mark a turning point. As wearables become more sophisticated, including sensors for oxygen saturation, heart rhythm, sleep apnea, or even glucose levels, regulators face mounting pressure to treat them as medical devices rather than lifestyle gadgets. For the industry, that could mean weighing innovation against compliance, agility against regulation — and convenience against trust.
For consumers, the message is clear: just because a wearable offers health-style features, doesn’t mean those features are as reliable as medical-grade tools.
Why this matters to anyone who uses a smartwatch or fitness tracker
In July 2025, the U.S. Food and Drug Administration (FDA) sent a warning letter to WHOOP, the maker of a widely used fitness and wellness wearable. The issue: WHOOP’s “Blood Pressure Insights” (BPI) feature estimates systolic and diastolic blood pressure — a measurement the FDA says pushes the device from casual wellness into regulated medical territory.
That’s a big deal. Instead of letting users get quick, convenient blood-pressure estimates from their wrist, the FDA’s move suggests that wearables like this now face much stricter rules.
What WHOOP claimed vs what FDA thinks
WHOOP maintains BPI is a wellness tool, designed to help users “understand how blood pressure interacts with sleep, stress, exercise and overall performance — not to diagnose or treat any medical condition.”
The FDA disagreed. In the warning letter it called BPI both “adulterated” and “misbranded,” because WHOOP never submitted the required regulatory filings before marketing the feature. The agency said blood pressure estimation is “inherently associated” with diagnosing hypertension or other conditions — putting it in the medical-device category.
What this could mean for wearables — including yours
Companies may need to invest heavily in clinical trials, cybersecurity, quality-control systems, and regulatory compliance before launching or continuing features like BPI.
Some smaller or niche wearable makers could struggle with the added cost and delay from approvals, possibly shelving features altogether or limiting what their devices claim to do.
Even big players could feel pressure: firms that want to add blood-pressure tracking may start seeking formal FDA clearance rather than risk enforcement.
For users, it could mean fewer “freebie” health features on wearables — or longer waits for them to become available.
What you should do now
If you use a wearable that claims to estimate or monitor blood pressure, recognize that such features may be downgraded, removed, or delayed — especially if the maker decides not to navigate the new regulatory burden. For non-essential tracking, stick to what the device was originally designed for (e.g., sleep, heart rate, steps). And if you need accurate blood pressure data for health reasons, a traditional cuff-based monitor remains the safer choice until wearables meet medical-device standards.
What the FDA Warning Letter Means for Wearable Tech Companies
The enforcement action by the U.S. Food and Drug Administration (FDA) against WHOOP illuminates a rapidly evolving regulatory landscape for wearable tech — one where the boundary between wellness and medical devices is increasingly contested, and compliance burdens are mounting.
In July 2025, the FDA issued a formal Warning Letter to WHOOP, concluding that its Blood Pressure Insights (BPI) feature constitutes an unapproved medical device. Under the governing statute, the Federal Food, Drug, and Cosmetic Act (FD&C Act), any product intended for diagnosing, mitigating, curing, preventing or treating disease — or affecting the structure or function of the body — must undergo pre-market review, clearance, or approval. The FDA determined that BPI meets this threshold.
WHOOP, for its part, argued BPI falls under the “general wellness” exemption under the 21st Century Cures Act. The company claims the feature helps users track how daily activities (sleep, stress, exercise) affect blood pressure — more like heart-rate variability or sleep‐tracking than a diagnostic tool. But in its Warning Letter, the FDA stressed that blood-pressure estimation “is inherently associated with the diagnosis of hypo- and hypertension,” meaning it can’t be shielded under general-wellness discretion.
Legal and regulatory analysts describe the FDA’s move as emblematic of a larger pivot. Several years ago, wearables offering basic tracking — steps, heart rate, sleep — operated under a de facto safe harbor: the regulatory gray zone. Now, as biometric sensors advance to offer more clinically relevant data — blood pressure, blood oxygen, potentially glucose in the future — regulators appear ready to draw a firm line.
For smaller or niche wearable makers, the practical implications are serious. To comply, companies may now need to:
Pursue pre-market pathways, such as 510(k) clearance or premarket approval (PMA).
Undertake clinical studies to validate the accuracy and safety of their estimations.
Invest in robust quality-management systems, cybersecurity protocols, and regulatory audits.
Redesign software and hardware to align with regulated-device standards.
These requirements carry real cost — both in time and money — which may delay product launches or suppress innovation. As one investment-industry voice put it: “What was once a land rush of health tech innovation is now seeing the regulatory sheriff ride into town.”
Larger established tech companies may absorb the burden more easily. Some firms are already seeking or obtaining FDA clearance for features like hypertension alerts. For others — particularly lean startups — the path forward looks more treacherous.
Moreover, the FDA’s action against WHOOP could prompt broader enforcement across the industry. Legal counsel warn that marketing any biometric estimation with clinical relevance — even if cloaked in lifestyle or wellness framing — may no longer evade scrutiny. The agency’s criteria appear to emphasize the function and risk profile of a feature, not only how it’s marketed.
This also raises strategic business questions — especially around compliance vs. innovation, and markets vs. regulation. Product roadmaps that once prioritized time-to-market and feature breadth may now need revisiting. Companies will need to consider fallback positions: focus solely on low-risk metrics (steps, sleep, heart rate) or invest in compliance infrastructure and enter the medical-device world.
For investors, regulatory risk quickly becomes financial risk. Startups valuing agility and rapid growth must weigh whether they can absorb the expense of clinical validation and regulatory overhead — or whether the pivot toward regulatory compliance is just too steep.
From a policy design perspective, the WHOOP case spotlights a tension at the heart of digital health: how to balance encouraging consumer access to health data with ensuring accuracy, reliability and public safety. As sensors and algorithms advance, regulators may increasingly prioritize function over marketing — defining a new regulatory era where biometric estimation isn’t just a feature, but a regulated responsibility.
In short, the wearable-tech gold rush may be over. The next phase looks more like regulated, tightly controlled real estate — where only the well-funded, the well-prepared, or the few willing to navigate compliance survive.
Impact and Implications
- Regulation FDA’s stance on Blood Pressure Insights establishes blood-pressure estimation as a regulated device function, increasing documentation, validation, and review requirements for any wearable feature that touches clinically meaningful cardiovascular metrics
- Startup ecosystems Smaller wearable firms now face higher upfront costs for clinical studies, regulatory counsel, and quality systems, which can narrow investment appetite and favor partnerships or acquisitions by larger, compliance-ready platforms
- Product design Roadmaps are shifting toward either fully regulated health features with formal clearance or lower-risk wellness metrics, influencing sensor choices, feature priority, and long-term maintenance obligations for software and firmware updates
- Consumer trust Clearer regulatory boundaries around blood-pressure tools aim to align marketing claims with proven performance, reinforcing expectations that clinically framed features behave more like medical devices than casual lifestyle add-ons
Fact Check
- Claim: Blood Pressure Insights is just a lifestyle add-on without medical consequences Fact: FDA says estimating blood pressure aligns with diagnosing hypertension, meeting the legal definition of a regulated medical device feature
- Claim: The warning letter bans blood-pressure features on all consumer wearables Fact: FDA requires authorization for features intended to measure or estimate blood pressure; compliant products can still offer validated blood-pressure capabilities
- Claim: Regulatory guidance still broadly exempts advanced wearables under the general wellness policy Fact: Recent analyses highlight the WHOOP letter as evidence that high-impact metrics like blood pressure receive narrower enforcement discretion
- Claim: Consumers may treat WHOOP’s estimates as replacements for clinical blood-pressure checks Fact: FDA cites hypertension guidelines stressing that inaccurate readings can influence treatment choices, reinforcing the role of validated medical-grade monitors
Editors Insight
- Regulatory turning point The WHOOP case illustrates how quickly a single enforcement action can recalibrate expectations across digital health, signaling that regulators now prioritize function and risk over marketing language when classifying wearable features
- Market reshaping Tighter oversight is nudging the wearables space toward a split between regulated, clinically oriented devices and lighter wellness trackers, a divide that will influence investment flows, partnerships, and product strategies over the next few years
- Consumer expectations As wearables adopt more medical framing, audiences will judge them less like gadgets and more like health tools, making transparency about validation, limitations, and regulatory status central to long-term credibility
Sources
- Reuters – FDA scrutiny of WHOOP signals challenges for niche wearable device makers: Original news report detailing the warning letter context and potential impact on smaller wearable manufacturers
- U.S. FDA – Warning Letter to WHOOP Inc. (July 14, 2025): Primary regulatory document outlining why Blood Pressure Insights is considered an adulterated and misbranded medical device
- Mintz – FDA Warning Letter Reminds Industry that Wellness Claims Only Go So Far: Legal analysis summarizing FDA’s reasoning on blood-pressure estimation and general wellness policy limits for digital health products
- Duane Morris – FDA Issues Warning Letter Classifying Wearable Blood-Pressure Monitor as a Medical Device: Advisory discussing how WHOOP’s marketing statements influenced FDA’s device classification and enforcement posture
- Arnold & Porter – FDA Warning Letter to Fitness Wearable Sponsor Signals Heightened Scrutiny: Context on broader implications for developers of connected devices that rely on wellness exemptions and software-based measurements
Explore Related Streets
Discover interconnected perspectives across the Knowledge Streets —each Street brings its own lens to the tech landscape.
Robot Streets
Robot Streets explores AI systems, humanoid machines, automation breakthroughs, and how robotics is reshaping work, industry, daily life, and the global economy.
TechGear Streets
TechGear Streets dives into gadgets, devices, wearables, and everyday tech—hands-on reviews, smart buying guides, and simple how-tos for real-life users.
AI Streets
AI Streets explores artificial intelligence breakthroughs, everyday tools, emerging risks, practical guides, and how AI reshapes business, creativity, work, and society.
3D Printing Street
3D Printing Street covers additive manufacturing, desktop printing, industrial-scale production, materials, design tools, and real-world applications shaping how products are created.
Nova Streets
Nova Streets explores everyday software from a user’s point of view—productivity tools, creative apps, business platforms, and more. We break things down with clear, hands-on insights, no jargon, and practical guidance that helps beginners and pros make smarter software choices..
Philo Street
Philo Street explores TVs, streaming, displays, home entertainment gear, and how new technology is changing the way we watch, browse, and discover content.
Key Takeaways
- FDA warning letter to WHOOP’s Blood Pressure Insights redefines a wellness feature as an unapproved medical device
- Regulators emphasize that estimating blood pressure is inherently clinical, tightening scrutiny on similar wearable capabilities across the market
- Niche and startup wearable makers face higher costs for trials, quality systems, and regulatory filings before launching advanced health tools
- Industry strategies are diverging between devices pursuing formal medical clearance and trackers avoiding clinical claims to stay in a lighter regulatory category
- Consumers are reminded that wrist-based estimates are not interchangeable with validated medical-grade blood-pressure monitors used in clinical care
- Legal and policy analysts view the case as a test of how far the wellness exemption can stretch in digital health
- Global wearables growth continues, but the compliance burden is reshaping which companies can compete on more sophisticated health metrics
More in Tech
Quick Facts & Numbers
- 2025 — FDA issues formal warning letter to WHOOP over Blood Pressure Insights feature marketing in the United States
- $90 billion — Estimated global wearables market size, spanning fitness trackers, smartwatches, and specialist health-monitoring bands
- 1 feature — Blood Pressure Insights tool at center of dispute over wellness-versus-medical device classification
- 1 day — Typical frequency of WHOOP Blood Pressure Insights systolic and diastolic blood-pressure estimations for users
- 2019 guidance — FDA General Wellness policy once seen as safe harbor for low-risk fitness-tracking software and devices
- 14 July 2025 — Date on WHOOP FDA warning letter, cited widely in legal and regulatory analysis
Timeline — How We Got Here
- May 2025: WHOOP meets with FDA officials to explain Blood Pressure Insights as a general wellness-oriented software feature
- Jun 2, 2025: WHOOP sends follow-up letter arguing Blood Pressure Insights qualifies for the Cures Act wellness exemption
- Jul 14, 2025: FDA issues formal warning letter labeling Blood Pressure Insights an adulterated and misbranded medical device
- Jul–Aug 2025: WHOOP releases public statements defending its wellness framing while law firms publish detailed regulatory analyses
- Dec 3, 2025: Reuters reports on broader implications for niche wearable makers as FDA scrutiny expands beyond WHOOP
Explore our other Tech related sites:
AIMakeMyDay
AI Gaming Street
AI Movie Street
AI Music Street
AI Streets
3D Printing Street
Cyber Security Streets
Mobile Streets
Nova Streets
Philo Street
Robot Streets
TechGear Streets
Telecommunication Streets
Knowledge Streets
Reactions & Buzz
- FDA officials: Maintain that any product estimating blood pressure falls within medical-device regulation because of direct ties to diagnosing hypertension
- WHOOP statement: Says Blood Pressure Insights offers wellness context, not diagnosis or treatment, and likens it to other common wearable metrics
- Regulatory lawyers: Describe the warning letter as a clear signal that wellness marketing language will not override clinically oriented functionality
- Digital health investors: Warn that rising compliance costs may narrow opportunities for smaller wearable startups competing against larger, well-resourced platforms
- Consumer health advocates: Welcome stronger oversight to ensure that health-related claims on wearables match validated performance and do not mislead users
- Competing device makers: Reassess roadmaps, with some pursuing formal clearance for blood-pressure features while others avoid high-risk clinical indicators entirely
Frequently Asked Questions
- What is the core dispute between WHOOP and the FDA over BPI? FDA classifies Blood Pressure Insights as an unapproved medical device, while WHOOP argues it is a wellness feature providing contextual estimations, not clinical-grade blood-pressure readings or diagnostic information
- Why does estimating blood pressure trigger stricter regulation for wearable devices? Blood pressure is a key factor in diagnosing hypertension and cardiovascular risk, so regulators expect validated accuracy, risk controls, and formal authorization before companies market it as part of consumer technology
- How does this case affect smaller or niche wearable manufacturers? Smaller firms face additional spending on clinical validation, regulatory strategy, and quality systems, which can slow launches, reshape product roadmaps, or push them toward less clinically sensitive wellness metrics
- Are consumers’ existing WHOOP devices or other wearables immediately changing? The warning letter targets WHOOP’s Blood Pressure Insights feature rather than basic tracking, but companies reviewing similar capabilities may pause rollouts, alter marketing claims, or seek clearance to avoid future enforcement
- What does this signal about the future of health data on wearables? As wearables offer more clinically relevant metrics, regulators are treating some functions as medical devices, pushing industry toward either full compliance pathways or a narrower focus on low-risk lifestyle indicators
Did You Know?
- FDA’s warning letter to WHOOP references national hypertension guidelines, highlighting how misread blood-pressure values can alter treatment decisions and patient follow-up recommendations
- Blood Pressure Insights uses sleep-based optical signals and demographics to estimate morning blood pressure, combining sensor data, algorithms and population models
- Legal analyses note this is one of the first high-profile tests of how far the United States wellness exemption stretches for advanced digital health products
- Some competitors have pursued 510(k) clearance for cuffless blood-pressure tools, framing their devices squarely within existing regulated medical-device pathways
